By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Inc. 

900 Davis Drive
P.O. Box 14505
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-941-6920 Fax: 919-941-6931

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: 2600
Symbol: ESALF.PK


Company News
Eisai Inc. (ESALF.PK) To Present Abstracts On Oncology Products And Pipeline At ESMO 2017 Congress 9/1/2017 8:09:31 AM
Eisai Inc. (ESALF.PK) Release: Lenvatinib Significantly Improved Overall Survival In Older Patients With Locally Recurrent Or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According To Results Of Subanalysis Of Phase III SELECT Trial 8/28/2017 7:39:12 AM
FDA Approves Eisai Inc. (ESALF.PK)'s FYCOMPA (Perampanel) For Use As Monotherapy For The Treatment Of Partial-Onset Seizures 7/27/2017 6:30:27 AM
Eisai Inc. (ESALF.PK) Submits Supplemental New Drug Application To FDA For Lenvatinib In First-Line Hepatocellular Carcinoma 7/25/2017 6:46:51 AM
Eisai Inc. (ESALF.PK) Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study Will Continue As Planned Based On Interim Safety Analysis By Independent Data Monitoring Committee (DMC) 6/21/2017 8:16:53 AM
Further Study Of Combination Of Eisai Inc. (ESALF.PK)'s Lenvatinib And Merck & Co. (MRK)'s Pembrolizumab In Previously Treated Patients With Metastatic Endometrial Cancer Supported By Interim Analysis Of Ongoing Phase Ib/II Trial 6/5/2017 6:18:01 AM
Eisai Inc. (ESALF.PK) Release: Lenvatinib Demonstrates Positive Results Vs Sorafenib Across All Endpoints In First-Line Phase III Non-Inferiority Trial Of Unresectable Hepatocellular Carcinoma (uHCC) 6/5/2017 6:13:03 AM
Eisai Inc. (ESALF.PK) Commits Funding To The 2nd Phase Of Global Health Innovative Technology Fund Activities 6/1/2017 1:13:05 PM
Eisai Inc. (ESALF.PK) Enters Into A New Joint Research Agreement With The Broad Institute To Develop An Antimalarial Medicine 5/31/2017 7:04:16 AM
Eisai Inc. (ESALF.PK) And Johns Hopkins University Extend Drug Discovery Collaboration With New Licensing Agreement 5/31/2017 6:28:36 AM